Vinotha Thomas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Vinotha Thomas has a total of 112 co-authors. Here are the top co-authors by number of shared publications:
- Ajit Sebastian
Department of Gynaecologic Oncology, Christian Medical College, Vellore, India
29 shared publications - Anitha Thomas
Department of Gynaecologic Oncology, Christian Medical College, Vellore, India
28 shared publications - Abraham Peedicayil
Department of Gynaecologic Oncology, CMC Hospital, Vellore, India
26 shared publications - Dhanya Susan Thomas
Department of Gynaecologic Oncology, Christian Medical College, Vellore, India
19 shared publications - Rachel Chandy
Department of Gynaecologic Oncology, Christian Medical College, Vellore, India
17 shared publications Anitha Thomas
11 shared publications
Latest Publications
- 30 August 2026
- Published by Springer Nature in Indian Journal of Gynecologic Oncology
- Vol. 24  (3) , 73
One Stage, Many Stories : Unravelling the Clinical Heterogeneity of Stage IIIC1 Cervical cancer
- 30 August 2026
- Published by Springer Nature in Indian Journal of Gynecologic Oncology
- Vol. 24  (3) , 73
One Stage, Many Stories : Unravelling the Clinical Heterogeneity of Stage IIIC1 Cervical cancer
- Open Access
- 10 August 2026
- Published by Ecancer Global Foundation in ecancermedicalscience
- Vol. 20
Comparison of Sedlis and Pretoria Gynaecologic Oncology criteria for adjuvant radiation after radical hysterectomy in non-high-risk cervical cancer
Comparison of Sedlis and Pretoria Gynaecologic Oncology criteria for adjuvant radiation after radical hysterectomy in non-high-risk cervical cancer Vinotha T
- 10 August 2026
- Published by Ecancer Global Foundation in ecancermedicalscience
- Vol. 20
Open AccessComparison of Sedlis and Pretoria Gynaecologic Oncology criteria for adjuvant radiation after radical hysterectomy in non-high-risk cervical cancer
Comparison of Sedlis and Pretoria Gynaecologic Oncology criteria for adjuvant radiation after radical hysterectomy in non-high-risk cervical cancer Vinotha T
- 25 June 2026
- Published by Springer Nature in Cancer Causes & Control
- Vol. 37  (7)
Serum human papilloma virus detection following treatment of cervical cancer: prevalence and its correlation with recurrence
The detection of human papilloma virus (HPV) in serum after treatment for cervical cancer warrants further investigation. To study the prevalence of serum HPV and correlate its presence with cervical cancer recurrence. This prospective cross-sectional study recruited 100 patients following treatment of HPV-associated cervical cancer between January 2023 and March 2024 at a tertiary care centre in South India. Patients who had completed treatment within the past 3 years were included. After obtaining consent, a one-time serum sample for HPV detection was analysed using a multiplex real-time PCR AnyplexTM II HPV HR detection assay (Seegene, Seoul, South Korea). The prevalence of serum HPV was correlated with disease recurrence and evaluated by Fisher's Exact test. The log-rank test assessed the differences in disease-free survival between cases with and without measurable serum HPV. Among the 100 patients, the prevalence of serum HPV was 18% (18/100), with genotype 16 being found in 83.3% (15/18) of cases. There were 27 recurrences, of which 15 (55.6%) had detectable serum HPV DNA. Disease recurrence was significantly associated with serum HPV (odds ratio: 29.17, 95% confidence interval: 7.32-116.24). Higher serum HPV DNA levels, as determined by semi-quantification (2 + and 3 +), were associated with an increased hazard ratio for recurrence (58.33, CI: 6.83-498.23). Kaplan-Meier disease-free estimates revealed a significant association between recurrence and serum HPV prevalence (p = 0.000). Serum HPV can be used in the detection of recurrence in post-treatment surveillance of cervical cancer and should be validated in a prospective, longitudinal study.
- 25 June 2026
- Published by Springer Nature in Cancer Causes & Control
- Vol. 37  (7)
Serum human papilloma virus detection following treatment of cervical cancer: prevalence and its correlation with recurrence
The detection of human papilloma virus (HPV) in serum after treatment for cervical cancer warrants further investigation. To study the prevalence of serum HPV and correlate its presence with cervical cancer recurrence. This prospective cross-sectional study recruited 100 patients following treatment of HPV-associated cervical cancer between January 2023 and March 2024 at a tertiary care centre in South India. Patients who had completed treatment within the past 3 years were included. After obtaining consent, a one-time serum sample for HPV detection was analysed using a multiplex real-time PCR AnyplexTM II HPV HR detection assay (Seegene, Seoul, South Korea). The prevalence of serum HPV was correlated with disease recurrence and evaluated by Fisher's Exact test. The log-rank test assessed the differences in disease-free survival between cases with and without measurable serum HPV. Among the 100 patients, the prevalence of serum HPV was 18% (18/100), with genotype 16 being found in 83.3% (15/18) of cases. There were 27 recurrences, of which 15 (55.6%) had detectable serum HPV DNA. Disease recurrence was significantly associated with serum HPV (odds ratio: 29.17, 95% confidence interval: 7.32-116.24). Higher serum HPV DNA levels, as determined by semi-quantification (2 + and 3 +), were associated with an increased hazard ratio for recurrence (58.33, CI: 6.83-498.23). Kaplan-Meier disease-free estimates revealed a significant association between recurrence and serum HPV prevalence (p = 0.000). Serum HPV can be used in the detection of recurrence in post-treatment surveillance of cervical cancer and should be validated in a prospective, longitudinal study.
- Open Access
- 1 May 2026
- Published by Elsevier in The Lancet Regional Health - Southeast Asia
- Vol. 49, 100768
A decision-support tool for management of advanced epithelial ovarian cancer in a single centre in India (CT PAUSE Nomogram): a prospective Study (2022–2024)
- 1 May 2026
- Published by Elsevier in The Lancet Regional Health - Southeast Asia
- Vol. 49, 100768
Open AccessA decision-support tool for management of advanced epithelial ovarian cancer in a single centre in India (CT PAUSE Nomogram): a prospective Study (2022–2024)
- Open Access
- 1 January 2026
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 37
Comparative performance of first-void urine and self-collected vaginal swabs against clinician-collected cervical samples using 2 HPV real-time assays in Indian women
To enhance participation of women in cervical cancer (CC) screening, we compared high-risk human papillomavirus (HR-HPV) DNA testing of first-void urine (FVU) and self-collected vaginal swabs (SCVSs) to the gold standard clinician collected cervical specimens (CCCSs). In this cross-sectional study, consecutive consenting women (n=295) identified for CC screening mainly from Gynaecology-Oncology out-patient clinics were enrolled from May to October 2024. All were educated to provide self-samples (FVU, SCVS) followed by CCCS. All samples were tested for HR-HPV by 2 real-time polymerase chain reaction assays: Alinity m HR-HPV assay and Allplexâ„¢ II HPV HR assay. Awareness of CC, its screening, prevention and acceptability of self-sampling methods were assessed through a questionnaire. All sample types showed identical concordance (93.9%)/discordance (6.1%) across both real-time assays. Using Alinity m, sensitivity and specificity of FVU vs. CCCS was similar to SCVS vs. CCCS, i.e., 83.3% (95% confidence interval [CI]=68.64%-93.03%) and 98% (95% CI=95.45%-99.36%) respectively. With Allplex, sensitivity and specificity of FVU vs. CCCS was 84.78% (95% CI=71.13%-93.66%) and 97.19% (95% CI=94.29%-98.86%) respectively; and that of SCVS vs. CCCS was 97.83% (95% CI=88.47%-99.94%) and 95.98% (95% CI=92.74%-98.06%) respectively. Majority were unaware of CC (86.4%), its screening (98.6%) or its prevention (96.9%). Majority of women (92%) preferred FVU for CC if screened at regular intervals. This study shows a favorable performance of FVU and SCVS in both assays. FVU is a scalable, non-invasive, acceptable and feasible alternative to CCCS, with the potential to intensify CC screening programs in low- and middle-income countries.
- 1 January 2026
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 37
Open AccessComparative performance of first-void urine and self-collected vaginal swabs against clinician-collected cervical samples using 2 HPV real-time assays in Indian women
To enhance participation of women in cervical cancer (CC) screening, we compared high-risk human papillomavirus (HR-HPV) DNA testing of first-void urine (FVU) and self-collected vaginal swabs (SCVSs) to the gold standard clinician collected cervical specimens (CCCSs). In this cross-sectional study, consecutive consenting women (n=295) identified for CC screening mainly from Gynaecology-Oncology out-patient clinics were enrolled from May to October 2024. All were educated to provide self-samples (FVU, SCVS) followed by CCCS. All samples were tested for HR-HPV by 2 real-time polymerase chain reaction assays: Alinity m HR-HPV assay and Allplexâ„¢ II HPV HR assay. Awareness of CC, its screening, prevention and acceptability of self-sampling methods were assessed through a questionnaire. All sample types showed identical concordance (93.9%)/discordance (6.1%) across both real-time assays. Using Alinity m, sensitivity and specificity of FVU vs. CCCS was similar to SCVS vs. CCCS, i.e., 83.3% (95% confidence interval [CI]=68.64%-93.03%) and 98% (95% CI=95.45%-99.36%) respectively. With Allplex, sensitivity and specificity of FVU vs. CCCS was 84.78% (95% CI=71.13%-93.66%) and 97.19% (95% CI=94.29%-98.86%) respectively; and that of SCVS vs. CCCS was 97.83% (95% CI=88.47%-99.94%) and 95.98% (95% CI=92.74%-98.06%) respectively. Majority were unaware of CC (86.4%), its screening (98.6%) or its prevention (96.9%). Majority of women (92%) preferred FVU for CC if screened at regular intervals. This study shows a favorable performance of FVU and SCVS in both assays. FVU is a scalable, non-invasive, acceptable and feasible alternative to CCCS, with the potential to intensify CC screening programs in low- and middle-income countries.
- 3 September 2025
- Published by Springer Nature in The Journal of Obstetrics and Gynecology of India
- Vol. 76  (3) , 218-225
A Comparative Analysis of Fertility-Sparing Surgery and Complete Staging Surgery in Early Stage Epithelial Ovarian Cancer: Impact on Oncological Outcomes
Background Fertility-sparing surgery (FS) is a viable option for women with early-stage epithelial ovarian cancer (EOC) desiring fertility preservation. However, its oncological outcomes remain debated. Methods This retrospective cohort study analysed 135 patients with FIGO (International Federation of Gynaecology and Obstetrics) stage I EOC, operated between 1st January 2011 and 31st December 2020, comparing clinicopathological characteristics and oncologic outcomes between women who underwent FS (n = 26) and comprehensive staging surgery (CS) (n = 109). Continuous variables were compared using a t-test and Mann-Whitney test, while categorical variables were compared using the Chi-Square test. Disease-free and overall survival were plotted using Kaplan–Meier curves and compared using a log-rank test. Results During this period, Stage I EOC constituted 13.9% of the patients with EOC who underwent surgery. Patients in the FS group were younger (mean age 28.6 years versus 43 years, p = 0.00), with higher rates of nulliparity (77% versus 15%, p = 0.00). Though the pathological profile of the tumours in both groups was similar, 12(46%) in the FS group had high-grade histology. The FS group had a poorer follow-up rate (70% versus 83%, p = 0.033), a higher recurrence rate (30% vs. 8%, p = 0.001), and shorter mean disease-free survival (84.78 months vs. 124.86 months, p = 0.002). Older age and FS were significant predictors of recurrence at 2 and 5 years. Conclusion This study suggests that FS may be associated with higher recurrence rates in early-stage EOC. Careful patient selection, precise surgical information, and thorough follow-up protocols are crucial to balancing oncological safety with reproductive goals.
- 3 September 2025
- Published by Springer Nature in The Journal of Obstetrics and Gynecology of India
- Vol. 76  (3) , 218-225
A Comparative Analysis of Fertility-Sparing Surgery and Complete Staging Surgery in Early Stage Epithelial Ovarian Cancer: Impact on Oncological Outcomes
Background Fertility-sparing surgery (FS) is a viable option for women with early-stage epithelial ovarian cancer (EOC) desiring fertility preservation. However, its oncological outcomes remain debated. Methods This retrospective cohort study analysed 135 patients with FIGO (International Federation of Gynaecology and Obstetrics) stage I EOC, operated between 1st January 2011 and 31st December 2020, comparing clinicopathological characteristics and oncologic outcomes between women who underwent FS (n = 26) and comprehensive staging surgery (CS) (n = 109). Continuous variables were compared using a t-test and Mann-Whitney test, while categorical variables were compared using the Chi-Square test. Disease-free and overall survival were plotted using Kaplan–Meier curves and compared using a log-rank test. Results During this period, Stage I EOC constituted 13.9% of the patients with EOC who underwent surgery. Patients in the FS group were younger (mean age 28.6 years versus 43 years, p = 0.00), with higher rates of nulliparity (77% versus 15%, p = 0.00). Though the pathological profile of the tumours in both groups was similar, 12(46%) in the FS group had high-grade histology. The FS group had a poorer follow-up rate (70% versus 83%, p = 0.033), a higher recurrence rate (30% vs. 8%, p = 0.001), and shorter mean disease-free survival (84.78 months vs. 124.86 months, p = 0.002). Older age and FS were significant predictors of recurrence at 2 and 5 years. Conclusion This study suggests that FS may be associated with higher recurrence rates in early-stage EOC. Careful patient selection, precise surgical information, and thorough follow-up protocols are crucial to balancing oncological safety with reproductive goals.
- 17 April 2025
- Published by Springer Nature in Indian Journal of Gynecologic Oncology
- Vol. 23  (2) , 1-4
Gossypiboma: A Sheep in a Wolf’s Clothing
- 17 April 2025
- Published by Springer Nature in Indian Journal of Gynecologic Oncology
- Vol. 23  (2) , 1-4
Gossypiboma: A Sheep in a Wolf’s Clothing
- 17 January 2025
- Published by Springer Nature in Indian Journal of Gynecologic Oncology
- Vol. 23  (1) , 1-8
Financial Toxicity and Optimal Care in Ovarian Cancer—Perspective from Low Middle Income Countries
- 17 January 2025
- Published by Springer Nature in Indian Journal of Gynecologic Oncology
- Vol. 23  (1) , 1-8
Financial Toxicity and Optimal Care in Ovarian Cancer—Perspective from Low Middle Income Countries
- Open Access
- 16 September 2024
- Published by Ecancer Global Foundation in ecancermedicalscience
- Vol. 18, 1769
Sex cord ovarian tumours over 10 years: a retrospective analysis of clinicopathological profile and outcome
Sex cord ovarian tumours over 10 years: a retrospective analysis of clinicopathological profile and outcome Mona Naman Shah1,a, Vinotha Thomas1,b, Anjana J
- 16 September 2024
- Published by Ecancer Global Foundation in ecancermedicalscience
- Vol. 18, 1769
Open AccessSex cord ovarian tumours over 10 years: a retrospective analysis of clinicopathological profile and outcome
Sex cord ovarian tumours over 10 years: a retrospective analysis of clinicopathological profile and outcome Mona Naman Shah1,a, Vinotha Thomas1,b, Anjana J
- 5 September 2024
- Published by Springer Nature in Indian Journal of Gynecologic Oncology
- Vol. 22  (4) , 1-7
Comparison of HPV DNA Detection in Self-Collected Urine and Vaginal Samples
- 5 September 2024
- Published by Springer Nature in Indian Journal of Gynecologic Oncology
- Vol. 22  (4) , 1-7
Comparison of HPV DNA Detection in Self-Collected Urine and Vaginal Samples